Celldex Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Celldex Therapeutics

06/08/2026 21:34

Celldex Therapeutics, Inc. CLDX.OQ reported a quarterly adjusted loss of 94 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -85 cents.  The mean expectation of fourteen analysts for the quarter was for a loss of $1.06 per share. Wall Street expected results to range from $-1.16 to -92 cents per share.
Revenue fell 97% to $22.00 thousand from a year ago; analysts expected $954.44 thousand. 
Celldex Therapeutics, Inc.'s reported EPS for the quarter was a loss of 94 cents​.
The company reported a quarterly loss of $73.5 million.
Celldex Therapeutics, Inc. shares had risen by 10.3% this quarter and gained 51.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 6.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Celldex Therapeutics, Inc. is $56.00, about 26.7% above its last closing price of $41.06
This summary was machine generated from LSEG data August 6 at 08:34 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.06
-0.94
Beat
Mar. 31 2026 
-1.14
-1.18
Missed
Dec. 31 2025 
-1.01
-1.22
Missed
Sep. 30 2025 
-0.90
-1.01
Missed